LSINCT5
LSINCT5, a 2.6 Kb polyadenylated, long stress-induced non-coding transcript on the negative strand, which localized in the nucleus and potentially transcribed by RNA polymerase III, acts as a candidate biomarker in multiple cancers.
Contents
Annotated Information
Name
LSINCT5: long stress-induced non-coding transcript 5 (HGNC nomenclature)
Characteristics
LSINCT5 is a 2.6 Kb polyadenylated, long stress-induced non-coding transcript that is on the negative strand, localized in the nucleus and potentially transcribed by RNA polymerase III.LSINCT5,The LSINCT5 transcript consists of a core sequence and two long interspersed elements (LINE 1M repeat and LINE 1ME repeat).[1].
LSINCT5 is located 829,825 bp downstream of the IRX4 gene and 31,529 bp upstream of the IRX2 gene, both genes closely related to tumor development. LSINCT5's disorder in gastrointestinal tumors may be the downstream effect of these two genes[2].
It belongs to the category of "Intergenic" in lncRNA classification.
Cellular Localization
- nucleus [1].
Function
LSINCT5 appears to play a role in cellular proliferation and also with the development of breast and ovarian cancers[1].
LSINCT5 may act as an oncogenic lncRNA by influencing many cellular processes, including proliferation, in the carcinogenesis of cancers such as breast cancer, ovarian cancer, and gastrointestinal cancer[2].
High expression levels of LSINCT5 were significantly associated with poor DFS (disease-free survival)and DSS (disease-specific )rates in both GC (gastric cancer)and CRC(colorectal cancer ) patients, which indicated that LSINCT5 is an independent prognostic indicator for the DFS and DSS rates of GC patients[2],
Diseases
- breast cancer, ovarian cancer, gastric cancer, colorectal cancer
Expression
LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues, relative to their normal counterpart. In addition, knocking down the expression of LSINCT5 in cancer-derived cell lines causes a decrease in cellular proliferation[1].
| Primer | Assay | Forward Primer | Reverse primer |
|---|---|---|---|
| LSINIT5 | qPCR | 5'-ttcggcaagctccttttcta-3' | 5'-gcccaagtcccaaaaagttct-3'[1] |
| Northern | 5'-agagagctagctgggcaccttcc-3' | 5'-cataggcagtggtgccaac-3'[1] | |
| Real-time PCR | 5'-ttttgattacgacgggttcc-3' | 5'-ttcggcaagctccttttcta-3'[1] | |
| L5 5'RACE | 5'RACE | 5'-actgcctatgcacaggctgg-3'[1] | |
| L5 3'RACE | 3'RACE | 5'-caccagaactacagcacttta-3'[1] | |
| GAPDH | 5'-catggccttccgtgttccta-3' | 5'-tgtcatcatacttggcaggttt-3'[1] |
The expression of LSINCT5 was significantly higher in GC and CRC tissues than in adjacent normal tissues. In addition, LSINCT5 expression was markedly increased in several gastrointestinal cancer cell lines compared with normal cell lines[2].
| siRNA | Sense Sequence | Antisense Sequence |
|---|---|---|
| LSINCT5-siRNA1 | 5'-GGAGACCUUGAUGGGACCU-3' | 5'-AGGUCCCAUCAAGGUCUCC-3'[2] |
| LSINCT5-siRNA2 | 5'-AGGUCCCAUCAAGGUCUCC-3' | 5'-UAGACCCAGAGAACAUCAG-3'[2] |
| LSINCT5-siRNA3 | 5'-CAGAGAUUUUACAGCUGUU-3' | 5'-AACAGCUGUAAAAUCUCUG-3'[2] |
| siRNA(negative control) | 5'- CCUACGCCACCAAUUUCGU-3' | 5'- CCUACGCCACCAAUUUCGU-3'[2] |
| qPCR Primer | Forward Primer | Reverse Primer |
|---|---|---|
| LSINCT5 | 5'-TTCGGCAAGCTCCTTTTCTA-3' | 5'-GCCCAAGTCCCAAAAAGTTCT-3'[2] |
| GAPDH | 5'-CCGGGAAACTGTGGCGTGATGG-3' | 5'-CCGGGAAACTGTGGCGTGATGG-3'[2] |
Sequence
>gi|299767353|gb|GU228577.2| Homo sapiens LSINCT5 non-coding RNA, partial sequence
000081 TCAAGTCAAA AACACATTTT TTTCTAGTAA TTTGTGTTCT AGTACAAATG TAGTCTCATT CTATTTATCA TGCAGGTTGC 000160
000161 TGATGTCCTT GGGGTTTGTT CTGTTGTTTG GAGTGGGATG TGACTTCAAT TGTATGTTAT TGTTGCTTTT CCAAGTGGAT 000240
000241 ACTCGGTTCC GTTGAGGGCG TTTACCTTTG TTCTGGTCAT ATATGATCAC CTTTATTATC TACTGAAGTC TGATGTTCTC 000320
000321 TGGGTCTATT TCTGTCCTTT CTGGTTTATT CCACTGGCCC ATTTGTCAAA CCCTGCACCA GAACTACAGC ACTTTAGTGG 000400
000401 CAGAGATTTT ACAGCTGTTT TTTTTATGCC TGGTGTCCTG GTGCTTCTCC TTCCTCTTTG CTCATCTTTT TAAGGGATTT 000480
000481 CCTAGCTATT GTTGCATGAC TGTTTTTCCA TGTAAACTTT ATTACCAATG TATAGCTATA AAAAATGCTT GCTGGGCCAG 000560
000561 GCGCGATGGC TCACACCTAT AATCCCAGCA CTTTGGGAGG CCGAGGCAGG TGGATCACGA GGTCAGGAGA TGGAGACCAT 000640
000641 CCTGGCTAAC ACGGTGGAAC CCCGTCTCTA CTAAAAAAAA TACAAAAAAT TAGCCGGGCG TGGTGGCGGG CGCCTGTAGT 000720
000721 CCCAGCTACT CGGGAGGCTG AGGCAGGAGA ATGGTGTGAA CCCAGGAGGC GGAGCTTGCA GTGAGCTGAG ATTGCACCAC 000800
000801 TGCCCTCCAG CCTGGGCTAC AGAGCAAGGA AAAAAAAATT CTTGCTGGCC TTAGAACTGG ATTAGTGTTA AATTTGTCTG 000880
000881 TTAGCTCTGC TAGAATTTGA CAACTTTATG ATAGCATGCT TCCTGCCGAA GATCAAGAAC TGCTTTTCAG CTGGTCAAGT 000960
000961 CCACCTGGGA GCCTTTGGAA AGCATTTGGA AGCTTTTCCC CTTAGGTTTT CCATCGTTTA TCAAGATCAT TCCTAAGAAC 001040
001041 TTTGTGGTTT TCACTGCTAT TTTAAACCGA GATGTTTCTC TCTCCTTATG TCTTCTAAGA GGTAATGTGG ATAGGTAAAA 001120
001121 AGGTGACTGA TTGTTGTGTG TTAGTTTTAT ATTCTCCTAA ATGTTTCTAA AGGCAATTTT TCATGATTTA GACAACTTAC 001200
001201 TTAACCTCAT GATCACGTTG ATCAATACAG TCAGCACTGA ATCTTCTCCT CCCCTCCAAA CACATGGATA AGGTGGATAA 001280
001281 GGAATATTTA ATTTTTTTTT TAAAAGCACA GCCGCCCATG AAAGCAAGGA AGGAGAATCT CTGTGGTACA GAAATGGGGT 001360
001361 TGGAGTCCCT GGGGTGATCA GTGCTGTGGC CACAGGACCA CTGTGGACCC AGAAGACCAG CAGCAGGGCC AACACCTGTC 001440
001441 CAGGGTGGGA AACCCTACCT CATCATGGGG TGACAGCCTC AGGGGCTCCG GGGTGACTGG ACTCTGACTG TGAACTGAGA 001520
001521 AGGGGTTGAA ACTGCTTTCC CTTCTCCCAC ACAGGCAGGG CTTCTGCTGA AATGAGCTTC TGCCAGAAAT ACCCCAGACA 001600
001601 CATTCAATAC TGAAATATGG ACCTGCAAAG TACCCATAGG CAGGACCCCA CCCTGGGCTA TTGCGGACTG GAGCCCCGAG 001680
001681 CAGGAGAGCC CACCCAGGCT TGGCTTTGGA GCTGGAGGAG ACAGCGGTGA ATGGAACTTC CGCTCAGGAT GGGGTCTGGA 001760
001761 ACACTGGGTT TGGGAACAAC TAAGAGTCTC ATAAAGGGAA GACATAGCAA GGCAGGTACA GAAATAGCAA GGCGATTGTT 001840
001841 CAGGGGCATT GAGCTAAGTA AGTATATATT ACATTCTTAA GTAAATACAT AAAAATCAAA TGTGTAAAAA AAACAGATGA 001920
001921 AAGAGAAATA GGCATTTTTT AAAATAGAAA TGTTGGAAAT GATTAATATT AGTGATGAAA TGAATTCAAG CTCTTTCCCC 002000
002001 CACGTAGCAG GCTGTGAGTT GGGTGATCAG GCAGGGGTGG GAGACCCATG GGGGAAGGGG CGGAAACAGA GCCAGTGGGG 002080
002081 CTGGGCATGG AGCTGAGTCC AATAGCATCA TAGGTCTGCT GTGGTACCCA ACCGATGCTC TGTCACCGGC AAGGGGTGTC 002160
002161 TGGTCTTGAG GCTCTTGCCT GCTGAGTGGA AAGATCTACG TCTTTCGGGA GACCTTGATG GGACCTTGGC TTCAGAAATG 002240
002241 TCTCCCCCGC TCTCGGGGGA GCTGCTGCCC CAGCTGGGTC TTTGGTCTGA CTGGGCTTTG AACACTCTCT CTGCCTGCTG 002320
002321 CTCCTCTCTC TGCTCAGCCC TGCCTGGCGC AGAGAGCTGG GCACCTTCCA CCCACCCCTG CTGGGATGCA TCAAGCTGTC 002400
002401 TCTCAGGAGG GCCCGGGCTC CTGGCTGCAG CTCTACCTGC CCAAGTCCCA AAAGTTCTCA CACTGCAGGT GCTGCCTCAA 002480
002481 CCTCCACCCA CTCAGCCTGC CAGCTACAAA CCTCTGAACT GCAGGGTAGA AAAGGAGCTT GCCGAAGGTC CCTGCCTGCC 002560
002561 TTGCCCCACA ATGTAGCCTC TCCCGGAAAG GCAAGCTCAG CCTCCACTGG AACCCACATC TGACATCTGT GTCCTATAGT 002640
002641 TGGCACC
Labs working on this lncRNA
- Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN, USA[1].
- From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China[2].
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Silva JM, Boczek NJ, Berres MW, Ma X, Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation[J]. RNA biology. 2011,8(3):496-505.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Xu MD, Qi P, Weng WW, Shen XH, Ni SJ, Dong L, et al. Long non-coding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer[J]. Medicine. 2014,93(28):e303.
